Regencell Bioscience Holdings Limited
RGCAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| B. Riley | downgrade | Buy →Neutral | Jan 2, 2018 |
| Macquarie | downgrade | Outperform →Neutral | Dec 6, 2017 |
| RBC Capital | downgrade | Outperform →Perform | Dec 6, 2017 |
| Moffett Nathanson | upgrade | Sell →Neutral | Dec 6, 2017 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 28, 2026 | $-0.01 | — | — | — |
| Jun 15, 2026 | $-0.01 | — | — | — |
| Nov 18, 2025 | $-0.00 | — | — | — |
| Jun 26, 2025 | $-0.14 | — | — | — |
| Oct 25, 2024 | $-0.00 | — | — | — |
| Jan 26, 2024 | $0.00 | — | — | — |
| Oct 27, 2023 | $-0.01 | — | — | — |
| Jan 30, 2023 | $-0.01 | — | — | — |
News
Regencell Bioscience (NASDAQ: RGC - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, FiscalAI reports. Regencell Bioscience Price Performance NASDAQ: RGC opened at $7.11 on Thursday. The stock has a 50-day simple moving average of $5.92 and a two-hundred day simple moving average of
ROANOKE, Va., Sept. 28, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2175 per share on the Company's common stock.
RGC Resources is a micro-cap natural gas utility with limited growth prospects and a small, stable service area. RGCO's earnings growth remains sluggish, with FY 2026 guidance implying just 1.2% year-over-year EPS growth and a PE of 15.7. The company offers a 4.04% forward dividend yield, supported by an 82-year dividend history and consistent annual payout increases.